Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for weight loss. The reason? Rising costs.| www.wbur.org
Take the latest online polls and share your opinion on trending topics. Get instant results and see how your views compare—only on Polls and Insights.| Polls and Insights